BDR Pharma launches Zisavel capsules to treat invasive aspergillosis and mucormycosis

The product will be available in 100 mg capsules and is the first line of treatment for the aforementioned fungal infections BDR Pharmaceutical has launched first-of-its kind generic drug, Zisavel capsules, for the treatment of invasive aspergillosis and mucormycosis. Zisavel belongs to the family of isavuconazole, a class of medications called azole antifungals. Isavuconazole plays an important role in the treatment of invasive aspergillosis. The product will be available in 100 mg capsules and is the first line of treatment for the aforementioned fungal infections. The price of the generic drug will be Rs 7992, for seven capsules which is 1/3rd the cost of present therapy available by Innovators. BDR Pharmaceutical aims to reduce the cost of therapy for invasive fungal diseases with isavuconazole to be on par with voriconazole and posaconazole (new-generation anti-fungal agents), making it more accessible to patients who are unable to afford it currently. Raheel Shah, Director of Business Development, BDR Group, said, "As medical science progresses and R&D strengthens, we will continue to meet our commitment to providing quality and affordable drugs to needy patients. The burden of fungus diseases varies substantially based on geography, type of infection, severity of the disease, and various other socioeconomic factors. This drug, developed by us, is a revolutionary product, available at 1/3 of the innovator brand price. Isavuconazole will play an important role in controlling the infection and overall life expectancy." He further added, "As a company, we believe that access to affordable healthcare is a fundamental right for every individual. We are committed to doing everything in our power to make our mucormycosis drug accessible and affordable to all those who need it, and we will continue to work towards a future where no one has to suffer due to a lack of access to healthcare." With the launch of this new drug, BDR Pharmaceutical addresses a significant gap in the therapy area, particularly for those patients belonging to underprivileged communities.